Pfiz­er's El­rex­fio, Astel­las' Veozah among new drugs rec­om­mend­ed for au­tho­riza­tion by Eu­ro­pean reg­u­la­to­ry com­mit­tee

The Eu­ro­pean Med­i­cines Agency’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) this week rec­om­mend­ed sev­en new drugs for au­tho­riza­tion, in­clud­ing Pfiz­er’s po­ten­tial mul­ti­ple myelo­ma block­buster el­ranatam­ab and Astel­las’ hot flash treat­ment fe­zo­line­tant.

El­ranatam­ab, mar­ket­ed as El­rex­fio, won an ac­cel­er­at­ed ap­proval in the US in Au­gust for re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma pa­tients who’ve had at least four pri­or ther­a­pies, in­clud­ing a pro­tea­some in­hibitor, an im­munomod­u­la­to­ry agent and an an­ti-CD38 mon­o­clon­al an­ti­body. Eu­ro­pean reg­u­la­tors are con­sid­er­ing El­rex­fio for con­di­tion­al au­tho­riza­tion af­ter just three pri­or ther­a­pies, and Pfiz­er has made clear that it’s fo­cused on ex­tend­ing the drug in­to ear­li­er lines of ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER